
Passage Bio Investor Relations Material
Latest events

Study Result
Passage Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Passage Bio Inc
Access all reports
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a proprietary gene therapy platform in collaboration with the University of Pennsylvania’s Gene Therapy Program to deliver adeno-associated virus (AAV)-based therapeutics directly to the CNS. Passage Bio’s pipeline includes treatments targeting conditions such as frontotemporal dementia, Krabbe disease, and other inherited neurodegenerative and neurodevelopmental disorders. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for Passage Bio Inc


Corporate Presentation
Passage Bio Inc


Corporate Presentation
Passage Bio Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PASG
Country
🇺🇸 United States